Exploring Early Data With Olaratumab In Soft Tissue Sarcoma
Let's dive into the details surrounding Early Data With Olaratumab In Soft Tissue Sarcoma.
- William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall ...
- For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
- Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the ...
- William D. Tap, MD, chief,
- Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with
In-Depth Information on Early Data With Olaratumab In Soft Tissue Sarcoma
The panelists, Brian Van Tine, MD, PhD; Shreyaskumar Patel, MD; Robin L. Jones, MD, MRCP; Jonathan Trent, MD, PhD; and ... Anthony P. Conley, MD, reviews Tony Philip, MD, medical oncologist, Monter Mark Agulnik, MD, and Victor Villalobos, MD, PhD, provide insight on the clinical relevance of overall survival versus ...
Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal ...
That wraps up our extensive overview of Early Data With Olaratumab In Soft Tissue Sarcoma.
